IOL Chemicals And Pharmaceuticals Ltd. (IOLCP) — Tipsheet

IOL Chemicals halts one unit for 10 days after fire at its Minoxidil plant

Tipsheet Editorial — Wed, 10 Jun 2026 17:55:05 GMT

A fire at the Minoxidil manufacturing unit was controlled without injury. Only Unit-9B is offline; all other operations continue.

What’s new

Fire broke out on 9 June 2026 at Unit-9B, the Minoxidil manufacturing unit.
No injuries or significant damage; fire was controlled quickly.
Unit-9B suspended for 8-10 days as precaution; all other units unaffected.

Why it matters

A single-unit shutdown for 8-10 days is a minor operational blip for a company running multiple plants. Management says assets are insured and the financial impact should not be significant. The incident is contained.

What we’re watching

Actual duration of the Unit-9B downtime beyond the stated 8-10 days.
Insurance claim details and any impact on Minoxidil supply.
Production schedule for the remaining seven days of the quarter.

The full read

IOL Chemicals reported a fire on 9 June 2026 at its Minoxidil plant, Unit-9B. The incident was controlled without injury or significant damage, but the unit will stay shut for 8-10 days as a precaution. That is the extent of the disruption. The company's other units are running normally, and management says the financial hit should not be significant, with assets adequately insured. For a Small Cap firm with multiple manufacturing sites, the shutdown of one unit for roughly a week and a half is a contained event. The filing is procedural.

Primary source: BSE · NSE

IOL paracetamol plant running at 55%, below its own target

Tipsheet Editorial — Fri, 22 May 2026 16:31:16 GMT

Management reaffirmed FY27 growth targets but disclosed a key capacity-utilization miss on its expanded paracetamol line. The stock trades at a discount to its own execution promises.

What’s new

Paracetamol capacity utilization is at 55%, missing the prior March 2026 target of 65%.
Management targets 70-75% utilization by FY27 and 100% by FY28 on the same line.
Ibuprofen demand recovered to 85-95% utilization after a destocking cycle.

Why it matters

The paracetamol line is the core of IOL's recent capacity expansion. Running it at 55% when the plan was 65% means the ramp is lagging, which delays the revenue and margin benefits the expansion was supposed to deliver. The revised path to 100% by FY28 is a long runway from a low starting point.

What we’re watching

Whether paracetamol utilization hits the 70-75% target by FY27 end.
Progress on the ₹1,200-1,400 cr greenfield capex plan over four to five years.
Non-ibuprofen portfolio gains from new European CEP certifications.

The full read

IOL Chemicals reaffirmed its FY27 guidance of 15-18% revenue growth and a 14% EBITDA margin. The key disclosure in the concall was that its expanded 10,800-tonne paracetamol plant is running at only 55% utilization, well short of the 65% target for March 2026. Management sketched a path to 70-75% by FY27 and 100% by FY28. The ibuprofen line recovered to 85-95% utilization after destocking, and the non-ibuprofen portfolio is gaining share through European CEP certifications. Separately, IOL detailed a ₹1,200-1,400 crore greenfield expansion over four to five years, funded internally. The paracetamol shortfall is the number to watch. It is the central asset of the recent expansion, and its ramp will determine whether the guided 14% EBITDA margin is achievable.

Primary source: BSE · NSE

IOL Chem's Q4 & FY26 results: Old news, no surprises

Tipsheet Editorial — Thu, 21 May 2026 12:53:59 GMT

Audited numbers and Triacetin/Pantoprazole expansions were already disclosed. Market knew the story.

What’s new

Audited standalone and consolidated results for Q4 & FY26 filed.
Board approved Triacetin and Pantoprazole capacity expansions.
All information was previously disclosed; this filing is procedural.

Why it matters

This is a routine closure of the books. The strong quarterly performance and minor capex were already in the public domain. Nothing here changes the investment thesis or near-term trajectory.

What we’re watching

Execution of the announced capacity expansions.
Any change in margin trajectory from the newly disclosed line-item details.
Q1 FY27 commentary on demand and pricing.

The full read

IOL Chemicals' annual results filing is a procedural box-tick. The audited numbers for Q4 and FY26 track the earlier announced provisional figures, and the Triacetin and Pantoprazole expansions were flagged in prior board meetings. No new surprises, no guidance revisions, no governance flags. For a company that delivered strong operating performance, the filing itself adds nothing the street didn't already know.

Primary source: BSE · NSE

IOL Chemicals hits record Q4 revenue of ₹619.5 cr, PAT up 68%

Tipsheet Editorial — Wed, 20 May 2026 18:39:47 GMT

Strong momentum in Pharma and Chemicals drives best-ever quarterly performance; ₹164 cr capex announced.

What’s new

Record Q4 revenue of ₹619.5 cr
PAT surges 68.2% to ₹53.2 cr
₹164 cr capex for expansion and automation

Why it matters

These are exceptional numbers, but the core financials were already disclosed. What changes here is the detail on segment momentum and a confirmed ₹164 crore capex cycle. The open question is whether this pace can be sustained into FY27.

What we’re watching

Sustainability of Pharma and Chemicals growth into FY27
Execution of ₹164 cr capex plan
Any margin pressure from raw materials

The full read

IOL Chemicals posted its best quarter ever in Q4 FY26, with revenue of ₹619.5 crore and PAT up 68.2% to ₹53.2 crore. The company said both Pharma and Chemicals segments drove the growth. It also disclosed a ₹164 crore capex programme for capacity expansion and automation, funded through internal accruals. However, this press release is a detailed reiteration of numbers already shared in the audited results. The quarter is strong, but the market has seen the headline figures. What investors gain here is colour on segmental strength and capex specifics, not new surprises.

Primary source: BSE · NSE